In this exclusive video from DDW 2016, Mark Pochapin, MD, from NYU Langone Medical Center, discusses Gastro Girl, a new online platform that provides support to patients with chronic gastrointestinal symptoms and conditions.
Gaithersburg-based Novavax Inc. plans to create up to 850 new jobs as part of its planned Montgomery County expansion and will receive state and county financial assistance to support the growth, it was announced Wednesday.
The Kansas City, Mo.-based Kauffman Foundation recently released its 2016 Kauffman Index of Growth Entrepreneurship and found — to the authors seeming surprise — that the Washington, D.C. metro area topped a list of U.S. metro areas with the most growth entrepreneurship.
I trained as a physician and scientist, having received both an MD and a PhD. I did my residency in pathology and about 11 years ago I decided to make the transition from academia to industry. Since then, most of my work has been focused on immunotherapy, which is a new and very exciting area of cancer research. Nine months ago I joined MedImmune, the global biologics arm of AstraZeneca, as the head of oncology development.
Digital health technology leader WellDoc® today announced results from a real-world study designed to evaluate the feasibility and reach of using a lay coach in conjunction with BlueStar® mobile prescription therapy to provide ongoing self-management support for people living with type 2 diabetes in a primary care setting. The data were featured via a poster presented today at the American Diabetes Association’s (ADA) 76th Scientific Sessions, taking place now at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
It’s no secret that one of the biggest things holding New York City’s biotech ecosystem back is lack of lab space for startups. The problem will take a broad effort to solve, not just a few buildings or incubators. But one of the city’s biggest real estate players, Alexandria Real Estate Equities, has announced a plan today to help out.
Innovation is the foundation of the 21st Century bioscience industry. It is an industry borne from scientific innovations involving techniques to understand and manage the machinery of living things. The advent of biotechnology in the 1970s, enabled work at the molecular and cellular level including moving genetic information from one living cell to another and tracing the pathways of disease. Over the last 40 years, bioscience innovation has advanced at an astonishing speed. Advances
Therapeutic proteins represent a number of the currently top 10 best-selling drugs and have combined sales of almost $64 billion per year. The enormous market potential for biosimilars or biobetters has created a crowded field of developers. As a result, there is a growing emphasis on emerging analytical techniques and their lifecycle appropriate application. Industrial, federal, and academic researchers will gather to discuss available open innovation resources and technological advancements for fueling biopharmaceutical development. On Thursday, June 23, 2016 at 8:30 AM join the thought leaders, policy makers, and developers of therapeutic proteins as we present current trends, ideas, and predictions on the use of open innovation biomanufacturing resources and emerging technologies.
The University System of Maryland plans to establish a $25 million fund to invest in startup companies created by students, faculty and recent graduates.
Two Fast Forward companies have been recognized as finalists. The companies are emocha Mobile Health: a mobile health platform that streamlines the continuum of care. and Sonavex Surgical; improving outcomes for surgical patients by using cutting-edge imaging technology to provide clinicians with visualization of critical data — directly at the point of care.
To be held June 23-24 2016 at the NCCOE facility located at 9700 Great Seneca Highway in Rockville.
There is a considerable body of knowledge, governance structures, tools and techniques that have been developed to address regional resilience from a physical infrastructure perspective. However, there has been little done to date to understand and address cyber resilience at a regional level. Even the definition of what constitutes regional cyber infrastructure and whether that is a useful context for examining regional resilience are open questions. As a result, a number of regional consortia, organizations, and programs have begun to focus on this regional cyber challenge and are considering options for addressing regional cyber resilience in a meaningful manner. Please join us on June 23-24 2016, for the inaugural Regional Cyber Resilience Workshop. The workshop will be held at the NCCOE facility located at 9700 Great Seneca Highway, Rockville, MD 20850.
The Maryland Department of Commerce is joining with the state’s top research universities and other life sciences partners and stakeholders to create two or more Centers of Excellence around the state to support cell, gene and regenerative therapies, as well as medical devices and 3-D printing. This partnership with The Johns Hopkins University, the University of Maryland, Baltimore and the University of Maryland, College Park will help position Maryland as a leader in commercialization and clinical translation of next-generation medicines and medical devices and ensure the state remains a leader in healthcare innovation. Additional partners include the Center for Medical Technology Policy and biotechnology, pharmaceutical, contract manufacturing, and medical device companies.
The cover of Ernst & Young’s 2016 biotech report has a picture of a parachutist and the subtitle, “Returning to Earth.” According to EY, the biotech industry has experienced explosive growth over the past few years, but that appears to have slowed in 2015. On its own, a 13 percent increase in biotech revenue looks impressive – unless it’s compared to the 18 percent increase in 2014.
Omicia has raised $23 million from Roche’s ($RHHBY) venture fund and other investors. The Series B round will support the expansion of Omicia’s NGS interpretation and reporting capabilities into new sectors, including clinical trials and life science research.
When Gabe Otte went to college, he already had an Apple internship under his belt. In undergrad, his computer-science professors told him to diversify and pick out another area to focus on so he wasn’t bored in class, so he chose biology.
The next Kendall Square just might be located in Allston.
The gritty Boston neighborhood, across the Charles from Harvard University’s main campus, is the site of various construction projects aimed at building up an innovation epicenter over the next five to 10 years. Just don’t tell Jodi Goldstein about the Kendall comparison.
Longitude Capital, an investment firm focused on venture growth investments in biotechnology and medical technology, closed its third fund, at $525m in partner commitments.
Governor Terry McAuliffe announced today $3.4 million in funding to support 48 Commonwealth Research Commercialization Fund (CRCF) awards representing targeted areas of promising research commercialization, including cybersecurity, energy, data analytics, unmanned systems and life sciences.
BioLogic, the Cincinnati region’s only life science incubator, is trying to turn local entrepreneurs’ ideas for improving human health into reality. Now the incubator has a new format, officially becoming a nonprofit a few weeks ago.
The incubator offers the only “wet-lab” space for lease within 100 miles, which allows startups to access expensive material and equipment typically limited to universities and hospitals.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
